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ABSTRACT
Reliable biomarkers are required to predict the response to sorafenib. 
We investigated genomic variations associated with responsiveness to sorafenib 
for patients with unresectable hepatocellular carcinoma (HCC). Blood samples from 
2 extreme, 2 strong and 3 poor responders to sorafenib were subjected to whole-
genome analysis. Then, we validated candidate genomic variations with another 174 
HCC patients, and performed in vitro functional analysis and in silico analyses. Genomic 
data of >96 gigabases/sample was generated at average of ~34X sequencing depth. In 
total, 1813 genomic variations were matched to sorafenib responses in clinical data; 708 
were located within regions for sorafenib-target genes or drug absorption, distribution, 
metabolism, and excretion (ADME)-related genes. From them, 36 variants were within 
the coding regions and 6 identified as non-synonymous single-nucleotide variants from 
4 ADME-related genes (ABCB1, FMO3, MUSK, and SLC15A2). Validation genotyping 
confirmed sequencing results and revealed patients genotype for rs2257212 in SLC15A2 
showed longer progression-free survival (HR = 2.18). In vitro study displayed different 
response to sorafenib depending on the genotype of SLC15A2. Structural prediction 
analysis revealed changes of the phosphorylation levels in protein, potentially affecting 
sorafenib-associated enzymatic activity. Our finding using extreme responder seems 
to generate robust biomarker to predict the response of sorafenib treatment for HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common types of cancers (with the highest prevalence 
in the Asia-Pacific region) and the third leading cause 
of cancer death worldwide. [1] Because this disease is 
mostly diagnosed at an advance stage, potentially curative 
therapies are effective in less than 30–40% of HCC 
patients. [2, 3] While systemic therapies are indicated for 
advanced HCC, no effective systemic therapy for patients 
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with advanced HCC existed until the development of 
sorafenib therapy. Sorafenib is a multikinase inhibitor 
that targets HCC angiogenesis, and it has been shown to 
impart survival benefits (2.8 and 2.3 months, respectively) 
on patients in Western and Eastern phase III randomized 
controlled trials. [4, 5] These trials have established 
sorafenib as a first-line treatment option for patients with 
advanced HCC, who have sufficiently preserved liver 
function. [2, 6]
Sorafenib is known to inhibit receptor tyrosine 
kinases in cell membranes (e.g., vascular endothelial 
growth factor receptors and platelet-derived growth 
factor receptor-beta) and downstream intracellular serine/
threonine kinases (e.g., Raf-1, wild-type B-Raf, and 
mutant B-Raf). These kinases are involved in tumor cell 
proliferation and tumor angiogenesis. In a previous study, 
sorafenib treatment resulted in dose-dependent inhibition of 
cell proliferation and induction of apoptosis in human HCC 
cells lines in vitro [7]; however, the precise underlying 
responsible mechanisms remain largely unknown.
Two phase III clinical trials have shown that about 
50–60 percent of the study subjects are non-responders to 
sorafenib treatment, and reliable biomarkers are needed for 
predicting treatment responses prior to therapy initiation. 
[8, 9] In practice, identification of good responders to 
sorafenib treatment may be critical for personalized 
therapy for management of advanced HCC. Unfortunately, 
no such reliable biomarkers or clinical factors currently 
have been identified to date. In addition, understanding 
the reasons for such differential responses is essential 
as is identifying stratification factors such as tumor 
molecular profiles and individual genetic differences in 
drug metabolism.
To distinguish good responders to sorafenib 
treatment from the poor responders, it is necessary to 
identify genes or markers related to the sorafenib response. 
However, conventional technologies such as massive 
PCR amplification and Sanger sequencing are time 
consuming and expensive; therefore, a single laboratory 
cannot undertake such a study independently. Recently 
developed molecular genetics technologies such as next-
generation sequencing (NGS) are innovative research 
tools for detecting genomic variations and are practical 
methods for detecting mutations with high accuracy. [10] 
In particular, whole-genome sequencing by NGS can be 
used to detect all genomic variations in exons, introns, 
and regulatory regions such as promoters and enhancers, 
[11, 12] allowing a systemic approach to biomarker 
identification. Consequently, challenges to identify genomic 
variations associated with drug response is emerged by 
analyzing the genome of exceptional responder by NGS. 
[13] As an effort to this, The National Cancer Institute 
(NCI) is funding for researches which are focused to 
“super responder” with hope to further identify patients of 
good responder using knowledge generated from super 
responder.
In this study, we present the results of a 
whole-genome sequencing analysis to identify sorafenib-
response markers and genes using the peripheral blood 
of HCC patients treated with sorafenib. From the patients 
who were treated with sorafenib, we selected two 
extraordinary responders who showed time-to-progression 
(TTP) more than 38 months and two good responders. 
With further three poor responder who showed less than 
5 month TTP, whole genome analysis was performed 
followed by bioinformatics analysis to compare their 
genomic variations. We identified genome-wide germline 
variations associated with the response to sorafenib 
treatment, especially in sorafenib-candidate targets and in 
absorption, distribution, metabolism, excretion (ADME) 
genes. Furthermore, we discovered that non-synonymous 
single-nucleotide variations (ns SNVs) in solute carrier 
family 15 (H+/peptide transporter) member 2 (SLC15A2) 
were functionally relevant to sorafenib metabolism by 
in silico and in vitro functional study. This finding was 
validated by genotyping of another 174 patients with HCC 
which revealed statistically significant progression-free 
survival (PFS) rate depending on genotype. This is the 
first report of precise identification of SNVs as associated 
with the extraordinary response to sorafenib treatment, and 
our results may prove useful for classifying patients with 




Table 1a shows the baseline demographics and 
clinical characteristics of the seven enrolled patients 
which were analyzed by whole-genome sequencing. 
Five (71.4%) patients were male and HBsAg-positive. 
Their median age was 60 years, and all were Child-Pugh 
class A. The seven patients were at Barcelona Clinic of 
Liver Cancer (BCLC) stages B (n = 4) and C (n = 3). The 
median of maximum tumor size was 45 mm, and two 
patients exhibited macrovascular invasion. According 
to time-to-progression (TTP) with sorafenib treatment, 
patients were arbitrarily classified into as being good 
responders (n = 4, Nr. 1, 2, 3 and 4 in Table 1a) harboring 
two extraordinary responders (Nr. 1 and 2) and poor 
responders (n = 3; Nr.5, 6 and 7 in Table 1a). A validation 
cohort (Table 1b) comprised 174 patients, with a median 
age of 56 years (interquartile range [IQR], 49–63) and 
84.5% were male. According to BCLC staging system, 
the number of patients with stage A, B, and C HCC were 
2 (1.2%), 35 (20.1%), and 137 (78.7%), respectively. 
Twenty patients (11.5%) were administered sorafenib 
as an initial treatment. The median overall survival 
(OS) and PFS of the validation cohort was 11.0 months 
(95% CI, 8.9–12.7) and 4.4 months (95% CI, 3.7–5.0), 
respectively.
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Table 1a: Baseline demographic and clinical characteristics of enrolled patients (n = 7)
Patient number 1 2 3 4 5 6 7
Sex Female Male Male Male Female Male Male
Age 54 45 47 60 61 66 68
Etiology HBV HBV HBV HBV HBV HCV HCV
mUICC stage IVa II III IVa II IVa III
BCLC stage C B B C B C B
Tumor 
morphology Infiltrative Multinodular Multinodular Multinodular Multinodular Multinodular Multinodular
Macrovascular 
invasion Yes No No Yes No No No
Maximum size 
of tumor (mm) 60 45 72 13 15 83 20
Child-Pugh 
class A A A A A A A
Serum AFP 
(ng/mL)
3505.9 3104.7 9.6 14 730.6 123016 23.9
TTP (mo) 55.5 38.1 9.3 8.1 4.7 3.5 4.3
Follow-up (mo) 62.2 55.4 60.5 33.1 4.9 14.5 15.5
Sorafenib 
response good good good good poor poor poor
mUICC, Modified International Union against Cancer; BCLC, the Barcelona Clinic of Liver Cancer; TTP, time to 
progression; HBV, hepatitis B virus; HCV, hepatitis C virus
Table 1b: Baseline characteristics of the validation cohort (n = 174)
Patient Characteristics (n, [IQR]) Tumor Characteristics
Age (years) 56 [49–63] Size of the largest nodule in the liver
Male 147 (84.5%) None 14 (8.1%)
Etiology ≤ 2 cm 22 (12.6%)
 HBV 135 (77.6%) 2–5 cm 47 (27.0%)
 HCV 13 (7.5%) >5 cm 91 (52.3%)
 HBV + HCV 2 (1.2%)
 Alcoholic 13 (7.5%)
 NBNCNA 11 (6.3%)
BCLC
Cirrhosis 140 (80.5%)  Stage A/B/C 1.2%/20.1%/78.7%
Bilirubin (mg/dL) 1.1 [0.7–1.6]
Prothrombin time (INR) 1.05 [0.9–1.15] Massive/infiltrative type 87 (50.0%)
Creatinine (mg/dL) 1.1 [1.0–1.2] Vascular invasion 95 (54.6%)
Albumin (g/dL) 3.9 [3.5–4.2]  Portal vein invasion 85 (48.9%)
AST (IU/L) 63.5 [43–106]  Hepatic vein invasion 25 (14.4%)
ALT (IU/L) 37 [26–72] Extrahepatic metastasis 84 (48.3%)
(Continued )
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Whole-genome analysis of patients genome 
by NGS
On average, >96 gigabase sequences per sample 
were generated with a ~32X mapping depth minimum and 
at a mapping rate of over 95% to the reference genome 
(NCBI build 37, HG19; Supplementary Table 1). This 
baseline value of whole-genome sequencing indicates 
that we obtained sufficient qualified sequencing reads to 
cover the entire genome. Using the final mapped bases, 
we constructed a genomic profile database for detecting 
SNVs, copy number variations, and structural variations. 
For each sample, we identified approximately 0.6 – 0.8 
million small indels and approximately 3.9 – 4.1 million 
SNVs. The majority of these SNVs was located in the 
intron, but a large proportion of SNVs was found in coding 
regions and splicing sites—including missense, nonsense, 
or frameshift mutations—which may cause functional 
changes of affected genes (Supplementary Table 2). The 
number of functional SNVs was approximately the same 
for all samples without any significant difference between 
good and poor responder. All data generated by whole 
genome sequencing was deposited in public database 
(NCBI SRA, Accession Nr. SRS 428124). Chip data 
generated by the genome-wide Axiom array were used for 
quality control of the identified SNVs (>99% concordance 
rate for each samples; Supplementary Table 3).
Identification of sorafenib response-associated  
variations
Genetic pattern analysis was used to identify genetic 
variations associated with drug responsiveness in the 
genomes of patients. Seven patients were assigned into 
two groups according to their sorafenib-responsiveness 
(good or poor responders). Alleles different from the 
human reference genome were coded as “A,” whereas 
alleles found the same as the reference genome were 
coded as “B.” This classification conferred four different 
genetic patterns in the response to sorafenib treatment, as 
shown in Supplementary Table 4. Subclasses 1 and 4 were 
dominant models in which “A” or “B” alleles dominantly 
contributed to the good sorafenib response, whereas 
subclasses 2 and 3 were recessive models whereby “A” or 
“B” homozygous alleles contributed to the good response 
to sorafenib treatment. We uncovered 1813 SNVs that 
were perfectly matched to one of these subclasses and 
identified as being 100% associated (Supplementary 
Table 5), 708 of which were located in the sorafenib target 
candidate genes or sorafenib ADME candidate genes 
(Supplementary Tables 6 and 7). Among the 708 SNVs, 36 
variations were SNVs located in genomic regions, 15 of 
which were located in the coding regions of nine genes 
(Table 2), all confirmed as being true-positive variants 
by Sanger sequencing. Thirteen of these 15 coding SNVs 
were confirmed to be located in the drug responsiveness-
related genes, whereas two of them were candidates 
as sorafenib target gene. Six coding SNVs were non-
synonymous, which cause amino-acid change and possibly 
damage the functions of their encoded proteins, and 
located in four genes: MUSK was a sorafenib target gene 
candidate; ABCB1, FMO3, and SLC15A2 were ADME 
genes (Fig. 1).
Pathway analysis
To further investigate sorafenib-associated variations 
at the pathway level, all variations were analyzed by gene 
positioning in the functionally annotated KEGG database. 
The genes that harbored 1813 genomic variations were 
mapped in the KEGG pathways; significantly affected 
pathways (P < 0.001) are displayed in Supplementary 
Table 8. Interestingly, the outcome of the pathway analysis 
was in accordance with that of the marker analysis, and 
the drug metabolism pathway (including its components 
such as FMO3 and ALDH3B1) were found to be the most 
significantly affected. This suggests that these genetic 
differences in the patients with HCC are involved in 
mechanisms implicated in different responses to sorafenib 
treatment.
Validation of sorafenib-associated SNVs in 
SLC15A2 and functional analysis
Since SLC15A2 belongs to the solute carrier family 
that supposedly participates in drug transport, we wanted 
Patient Characteristics (n, [IQR]) Tumor Characteristics
Child-Pugh class (A/B) 82.8%/17.2% AFP (ng/mL) 181.5 [16.3–2544.5]
MELD* 8.8 [7.7–10.6]  ≥ 200 85 (48.9%)
Number (proportion) or median [interquartile range] are shown.
HBV, hepatitis B virus; HCV, hepatitis C virus; NBNCNA, non-B/non-C/non-alcoholic; INR, internationalized normalized 
ratio; MELD, Model for End-Stage Liver Disease; AFP, alpha-fetoprotein; UICC, International Union Against Cancer; 
BCLC, Barcelona Clinic Liver Cancer
*The MELD score was calculated according to the original formula without rounding or lower and upper bounds in the 
variables and the final score.
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Table 2: Coding variants in candidate genes
Gene Chromosomea Positionb Refc Variantd Ref amino acide Variant amino acidf
ABCB1 chr7 87160618 A C S A
ALDH3B1 chr11 67795299 G A P P
ALDH3B1 chr11 67795353 G A L L
CYP21A2 chr6 32006317 C T L L
DDR1 chr6 30865204 A C P P
FMO3 chr1 171076966 G A E K
MUSK chr9 113538122 G A M I
SLC15A2 chr3 121646641 A G A A
SLC15A2 chr3 121643804 C T L F
SLC15A2 chr3 121641693 G A A A
SLC15A2 chr3 121647286 C T P S
SLC15A2 chr3 121648168 G A R K
SLC22A15 chr1 116534852 C T S S
SLC7A7 chr14 23282449 C T S S
SLC7A7 chr14 23282110 A G I I
aChromosome on which the variation was located
bNucleotide position of the variant allele in the human reference genome sequence version 19/build 37
cNucleotide at the same position in human reference genome sequence version 19/build 37
dNucleotide at the variation site
eAmino acid encoded by the corresponding codon in the reference sequence
fAmino acid encoded by the corresponding codon in the variant sequence
Figure 1: Schematics of six non-synonymous SNVs located in 4 genes. Schematics of six non-synonymous SNVs located in four 
genes (MUSK, ABCB1, FMO3, and SLC15A2), illustrated with functional domains (arrows indicate the locations of variants; numbers 
indicate the position of amino acids.)
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to validate the genomic variations in SLC15A2. From five 
coding variants in SLC15A2 identified by NGS analysis, 
we selected three non-synonymous SNVs (L350F, P409S, 
R509K), which may cause functional alteration in the gene 
product, and analyzed the genotypes for an additional 
174 HCC patients (Table 1b). We obtained individual 
genotypes of these three SNPs, which displayed complete 
linkage disequilibrium (Supplementary Table 9). Because 
of missing clinical data, we could only analyze PFS but 
not TTP. However, upon analyzing the association between 
genotypes and the PFS of these patients, we observed 
that cohorts of patients with C/C genotype for rs2257212 
(correspond to L350F) showed shorter progression-free 
survival time compared to the group of patients with C/T 
or T/T genotype (HR, 2.18; 95% CI, 1.15–4.15; P = 0.018) 
as it was indicated by NGS analysis. The Kaplan-Meier 
plot displayed significant genotype-dependent difference 
for PFS of 174 patients (Fig. 2) which may be caused by 
different drug responsiveness for sorafenib. Additional 
analysis by pair-wise addition of SNPs in coding variants 
to Cox proportional hazard model with SLC15A2 did not 
significantly improve model predictability (data not shown).
Further, we analyzed the functional effect of a non-
synonymous variant in SLC15A2. For in vitro functional 
analysis, we first identified the variant genotypes of 
rs2257212(L350F) in several human HCC cell lines and 
found that Hep3B, PLC/PRF5, and SNU182 possessed 
the C/C, C/T and T/T genotypes, respectively (Fig. 3A). 
Consistent with the results of whole-genome analysis and 
validation study, the T variant of rs2257212 in SLC15A2 
showed a better response to sorafenib than the C variant. 
Although the proliferation of cell lines was inhibited by 
sorafenib treatment in a dose-dependent manner, SNU182 
cells that harbored the T/T genotype displayed a better 
response to sorafenib than the Hep3B cells that harbored 
the C/C genotype (Fig. 3B). Additional western blot 
analysis showed similar SLC15A2 expression levels in all 
three cell lines (Fig. 3C), suggesting that structural, rather 
than expressional, changes were the cause of the function 
aberration.
DISCUSSION
Cancer biomarkers predicting outcomes of drug 
treatment may be used to assess the probability that a 
patient will benefit from a particular regimen of cancer 
treatment. [14] Previous biomarker response studies have 
evaluated the correlation between plasma angiogenesis 
biomarkers, alpha-fetoprotein (AFP) level or vascular 
permeability-perfusion of dynamic magnetic resonance 
imaging, and responses to sorafenib in patients with 
advanced HCC. [15–17] However, finding reliable 
biomarkers is not an easy task and none of biomarkers 
are clinically applicable to date. Recent approaches 
focusing comprehensive genome analysis of extraordinary 
response patients give rise to hope to identify genomic 
alterations associate with drug response. Especially, 
two studies identified genomics alterations related to 
drug responses by analyzing “outlier” responder in lung 
cancer patients. [18, 19] Here, we analyzed four good 
responder of sorafenib and one of them is extreme outlier 
with more than 55 months TTP although disease stage 
Figure 2: Kaplan-Meier plot depicting the progression-free survival of the validation cohort according to the SLC15A2 
genotype. Progression-free survival was significantly longer for patients with C/C genotype compared with those with C/T or T/T 
genotypes (HR: 2.18; 95% CI, 1.15–4.15; P = 0.018).
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at the beginning of treatment was IVa by mUICC stage. 
One other patient also showed extraordinary response 
to treatment with more than 38 months TTP. Our study 
represents the first effort to identify sorafenib-response 
variations and related genes through whole-genome 
analysis of HCC patients.
This study was conducted in a phase II clinical trial 
setting (named COTSUN), whereby the safety and efficacy 
of concurrent TACE and sorafenib in patients with HCC 
was evaluated. [20] TACE used as a locoregional therapy 
may not directly affect the sorafenib response and, in the 
present study, clinical characteristics were well collected 
and balanced between the good and poor responder 
cohorts; hence, we used blood samples from prospectively 
collected specimens from the COTSUN trial. Using blood 
samples from such a study is more convenient than using 
tumor specimens in terms of availability of biomarkers.
A total of 1813 genomic variations with 100% 
association for sorafenib responsiveness was discovered 
in this study. Among these, six non-synonymous SNVs 
were located in one sorafenib target gene (MUSK) and 
three ADME genes (ABCB1, FMO3, and SLC15A2), 
which could be considered as the member of main causes 
for sorafenib drug responsiveness, possibly by influencing 
protein function. To the best of our knowledge, this is the 
first to report suggesting that MUSK, ABCB1, FMO3, and 
SLC15A2 could be indicative for the response to sorafenib 
in patients with HCC. Among the four candidate genes 
Figure 3: Functional analysis of SLC15A2 variant in liver cancer cell lines. Three liver cancer cell lines were selected after 
their genotypes were validated by Sanger sequencing A. MTT assay after sorafenib treatment revealed that cell viability of the Hep3B cell 
line harboring the C/C genotype was considerably less affected than that of the SNU182 cell line harboring T/T genotype B. Western blot 
analysis showed similar expression SLC15A2 levels for all cell lines, irrespective of the genotype, which may indicate structural changes 
in the protein and which may be responsible for the differential drug response C. (** indicate P < 0.05, *** indicate P < 0.01)
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that we identified in this study, ABCB1 is a member 
of the superfamily of ATP-binding cassette (ABC) 
transporters. Interestingly, for Asian nasopharyngeal 
carcinoma patients, polymorphisms in the ABCG2 
and ABCB1 genes could be predictive markers of drug 
(irinotecan) activity. [21] The FMO3 gene is a type of 
flavin-containing monooxygenase, which is a member of 
an important class of drug-metabolizing enzymes. [22–24] 
Unfortunetly, the results from our validation set of patients 
and in vitro study did not confirm a meaningful association 
between these genes (ABCB1, FMO3) and the response 
to sorafenib (data not shown). These may be caused by 
marginal number of patients or multiple variations could 
be associated simultaneously which should be further 
analyzed.
The most interesting result of this study was the 
identification of non-synonymous single nucleotide 
variations in SLC15A2 as an important predictor of the 
response to sorafenib treatment in patients with HCC. 
SLC15A2 belongs to the family of proton-coupled 
peptide transporters that is responsible for the absorption 
of small peptides, as well as beta-lactam antibiotics and 
other drugs. [25] In our whole-genome analysis, the 
variations in this gene were found to be associated with 
sorafenib responsiveness and this result was validated in 
the practice-based cohort of 174 patients who were treated 
with sorafenib (Fig. 2; Table 1b). Patients with the T/T or 
C/T genotype displayed a significantly longer PFS than 
did patients with C/C genotypes (P = 0.003) maybe caused 
by better response to sorafenib. In the in vitro study, 
the suppression of HCC cell proliferation by sorafenib 
displayed greater dominance in SNU182 (an HCC cell line 
that was T/T homozygous for SLC15A2) compared to that 
in Hep3B (an HCC cell line that was C/C homozygous 
for SLC15A2). Taken together, our findings indicate that 
the functional impact of coding variants in SLC15A2 may 
affect sorafenib metabolism and responsiveness.
When we consider the results of in vitro assays in 
which similar SLC15A2 expression levels were observed 
in cell lines with different genotypes, the functional 
mechanism of the SLC15A2 variants should be related 
not to the change of expression level but to the structural 
changes caused by these variants. Although in silico 
analysis for three-dimensional structure prediction did not 
display substantial differences between both genotypes 
(data not shown), computational analysis (pubmed id: 
15980458, kinasephos.mbc.nctu.edu.tw) of post-
translational modifications revealed that protein generated 
from genes with variant genotypes (identified in good 
responders) may have more potential phosphorylation 
sites than wild type (identified in poor responders), 
as shown in Supplementary Table 10. The increased 
number of phosphorylation sites of SLC15A2 may 
delay the dephosphorylation of the protein, contributing 
to the longer activation required for SLC15A2, such 
that it could participate more in the mechanism of the 
sorafenib reaction. Together, patients with variant types 
of SLC15A2 may possess advantages in the effectiveness 
and responsive to sorafenib treatment because of the 
increased stability of the SLC15A2 protein which should 
be involved in the transport of this drug.
The analysis of gene-to-gene connection using 
the Liver hepatocellular carcinoma data in c-BioPortal 
(http://www.cbioportal.org/public-portal/) showed the 
association of SLC15A2 with cystic fibrosis 
transmembrane conductance regulator (CFTR) via 
PDZ domain containing 1 or 3 (PDZK1 or PDZD3; 
Supplementary Fig. 1). CFTR, a well-established 
member of the ATP-binding cassette (ABC) transporter 
superfamily, transport various molecules across 
extracellular and intracellular membranes. Polymorphisms 
of CFTR are known to be associated with benefit for 
clinical evaluation. [26, 27] Also, molecular alteration of 
PDZK1 may be associated with metabolic syndrome and 
drug-resistance phenotype in multiple myeloma. [28, 29] 
Additionally, many members of solute carrier family 
were revealed, especially the organic cation transporter 
OCT/OCT novel (OCTN) family. SLC22A4 (OCTN1) 
and SLC22A5 (OCTN2) were linked with SLC15A2 via 
PDZK1 and/or PDZD3. Interestingly, recent study reported 
that the polymorphisms of these genes are associated with 
prolonged TTP in unresectable gastrointestinal stromal 
tumors treated with imatinib therapy. [30] Taken together, 
the results of this network analysis provide additional 
evidence for the functional relevance of SLC15A2 in the 
response to sorafenib treatment.
SLC15A2 may transport many clinical and 
experimental therapeutic compounds, including beta-
lactams, angiotensin-converting enzyme inhibitors, 
5-aminolevulinic acid, bestatin, and pro-drugs such as 
Val-acyclovir and Val-ganciclovir. [31, 32] Previous 
reports have shown that different haplotypes of these 
variants exhibited markedly different Km values for 
glycyl-sarcosine (Gly-Sar). [33] Moreover, these 
variants revealed ethnic disparities for which Caucasian 
(0.371–0.500) and European (0.465–0.492) possessed 
lower frequencies of the T allele in than the Asian 
population did (0.744–0.800) [http://www.ncbi.nlm.nih.
gov/projects/SNP/]. These disparate frequencies may 
provide one possible explanation for the differential 
responses to sorafenib treatment vis à vis ethnicity. 
Although validation with the independent cohort of this 
study displayed a predictive significance to SLC15A2 
genetic variation, further prospective clinical studies are 
needed to confirm the predictive and/or prognostic values 
of SLC15A2 genetic variation in responses to sorafenib 
treatment.
In conclusion, we discovered genomic variants 
and their genes that should be associated with sorafenib 
responses for patients with HCC which could be used 
as biomarkers for predicting the effectiveness of drug 
responses. This is also the first report showing a significant 
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influence of the SLC15A2 genotype on the response to 
sorafenib in patients with HCC; our results suggest 
that SLC15A2 is a novel gene involved in sorafenib 
metabolism. Although further prospective validation 
and functional studies are needed, our results provide 
the initial clues for classifying patients with HCC by 
predicting the outcome of sorafenib treatment and for 
tailoring individualized therapy for these patients.
MATERIALS AND METHODS
Patients and specimen collection
The whole genome of seven patients was used for 
NGS analysis. Six patients were selected from a cohort 
of 50 patients with HCC, who were enrolled in a phase 
II study of concurrent transarterial chemoembolization 
(TACE) and sorafenib treatment. [20] Another patient 
was selected from a patient cohort displaying a long-
term (>48 weeks) response to sorafenib treatment. [34] 
HCC was diagnosed by histological examination or 
on the basis of clinicoradiologic criteria based on the 
guidelines of the Korean Liver Cancer Study Group and 
the National Cancer Center (NCC), Republic of Korea. 
[35] A validation cohort was derived from 408 patients 
with HCC who had been treated with sorafenib for greater 
than a 6-week period between June 2007 and March 2012 
at the NCC. [36] Fifty-seven patients who were lost to 
follow up or who discontinued sorafenib treatment due to 
non-medical issues were excluded. Out of the 351 patients, 
blood samples were obtained from 174 patients and were 
subsequently used for genotyping (Supplementary Fig. 2). 
This study was conducted in accordance with the 
Declaration of Helsinki and International Conference on 
Harmonization-Good Clinical Practice. The study protocol 
was approved by the Institutional Review Board at the 
National Cancer Center (Goyang, Republic of Korea). All 
patients provided us with their written informed consent to 
undertake the study.
Nucleic acid preparation and whole-genome 
sequencing
Genomic DNA was extracted from patient 
leukocytes by a MagAttract DNA Blood Midi Kit (Qiagen, 
Inc. Valencia, CA, USA) according to the manufacturer’s 
protocol. The DNA quality was assessed using a Nanodrop 
spectrometer (Nanodrop Technologies, Wilmington, DE, 
USA). An absorbance 260/280 value greater than 1.7 was 
accepted for further analysis. Five micrograms of genomic 
DNA was sheared using a Covaris S series ultrasonicator 
(Covaris, Woburn, MA, USA). The fragments of sheared 
DNA were then end-repaired, A-tailed, ligated to pair-
end adapters (Pair End Library Preparation Kit, Illumina, 
CA, USA), and amplified by PCR according to the 
manufacturer’s protocol. The quality of the library and 
DNA concentration were determined using an Agilent 
2100 BioAnalyzer (Agilent, Santa Clara, CA, USA) 
and quantified using a SYBR green qPCR protocol 
on a LightCycler 480 (Roche, Indianapolis, IN, USA) 
according to Illumina’s library quantification protocol. 
Paired-end sequencing (2 × 100 bp) was performed on an 
Illumina HiSeq 2000 by using HiSeq Sequencing kits
Read alignment and variation detection
Next, 90-bp paired-end sequence reads with ~300-bp 
inserts were aligned to the hg19 human reference genome 
(NCBI build 37) by using a BWA algorithm1 ver. 0.5.9. 
Two mismatches were permitted in the 45-bp seed 
sequence. SAMtools were used to remove PCR duplicates 
of the sequence reads, which may have been generated 
during the library construction process. The aligned 
reads were realigned at putative insertion/deletion (indel) 
positions by using the GATK IndelRealigner algorithm 
to enhance mapping quality. [37] Base quality scores 
were recalibrated using the GATK TableRecalibration 
algorithm.
SNP and small indel analysis
Putative SNVs were called and filtered using the 
UnifiedGenotyper and VariantFiltration commands in 
GATK. The options used for SNP calling were a minimum 
of 5 to a maximum of 200 reads in terms of mapping depth 
with a consensus quality of 20, and the prior likelihood for 
heterozygosity value of 0.001. To obtain small indels, the 
dINDEL mode of the GATK UnifiedGenotyper was used.
Validation of SNVs by using genome-wide SNP 
chips and Sanger sequencing
SNP genotyping to confirm the NGS data was 
performed using an Axiom genotyping solution with an 
Axiom Genome-Wide ASI 1 Array Plate (Affymetrix, 
Santa Clara, CA, USA) and a reagent kit according to the 
manufacturer’s protocol. Total genomic DNA (200 ng) 
was used and the resulting data in the form of a DAT file 
was automatically saved as a CEL file. The CEL intensity 
file was normalized, and genotype calling was performed 
using Genotyping Console 4.1 (Affymetrix) with 
Axiom GT1 algorithms according to the manufacturer’s 
instructions. The cutoff value for data quality control 
was a DISHQC ≥ 0.82 for hybridization and a QC call 
rate ≥ 97%.
Twenty-six SNVs, including 15 coding variations, 
were validated by conventional Sanger sequencing using 
dye-terminator chemistry. The sequences were analyzed 
using an automatic sequencer ABI 3730 (Applied 
Biosystems, Carlsbad, CA, USA). The target regions were 
amplified by PCR followed by direct sequencing or were 
cloned into TA vectors. Details of the PCR and sequencing 
primers are provided in Supplementary Table 11.
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Annotation and in silico analysis of variations
Each SNV was mapped onto the UCSC gene table 
according to its genomic features such as coding region, 
untranslated region (UTR), and introns. Non-synonymous 
SNV information was extracted by comparing UCSC (http://
genome.ucsc.edu/) reference gene information. Pathway 
analysis was performed for the genes annotated to harbor 
significant mutations by using the Kyoto Encyclopedia 
of Genes and Genomes (KEGG; 32, http://www.genome.
jp/kegg/) and Biocarta (http://www.biocarta.com/). 
For structural analyses of variations in SLC15A2, RefSeq 
NM_001145998 was used. Three-dimensional structures 
were generated using Phyre 2.0 (http://www.sbg.bio.ic.ac.
uk/phyre2/html/page.cgi?id=index). Post-translational 
modification was analyzed using KinasePhos (kinasephos.
mbc.nctu.edu.tw). Integrative analysis for SLC15A2 with 
publicly available data and pathways was performed by the 
cBioPortal website (www.cbioportal.org).
Validation of candidate SNPs and 
Statistical analyses
To validate the candidate SNPs, 174 patients with 
HCC who had been treated with sorafenib were genotyped 
using the MassARRAY system (Sequenom, San Diego, 
CA, USA) as previously described.[38] Progression-free 
survival (PFS) was assessed by the Kaplan-Meier method, 
and the association between generic polymorphisms and 
risk for progression was assessed by Cox proportional 
hazard model with adjustment by stage of hepatocellular 
carcinomas. Hazard ratios and their 95% confidence 
intervals (95% CI) were computed. Data analyses were 
performed using STATA version 12.0 (Stata Corp, College 
Station, TX, USA)
Validation and functional analysis of SLC15A2
Hep3B, PLC/PRF5 and SNU182 cells derived 
from human HCCs were obtained from the Korean 
Cell Line Bank (KCLB; Seoul, Republic of Korea) and 
cultured in RPMI-1640 (Invitrogen, Carlsbad, CA, 
USA) with 10% (v/v) FBS and 100 U/mL penicillin-
streptomycin at 37°C in 5% CO
2
. Genomic DNA was 
extracted from cells using a MagAttract DNA mini M48 
kit (Qiagen) according to the manufacturer’s instructions. 
For analysis of the SLC15A2 genotypes, genomic 
DNA was amplified by PCR using SLC15A2 primers, 
forward: (5′-GGGTCTTGGGTGTAAATGGA-3′), 
reverse: (5′-CACACTTGGAGACCAGACGA-3′), 
and sequenced as described above. For the MTT 
assay, cells were plated in 96-well plates at a density of 
1 × 104 cells/well and treated with sorafenib for 48 h in 
RPMI-1640 medium. Next, the number of viable cells 
was measured by performing MTT assay (Promega 
Fitchburg, WI, USA) according to the manufacturer’s 
instructions. For western blot analysis, 30 μg of each cell 
lysates was resolved on 4–12% NuPage gel (Invitrogen) 
and then transferred onto Immobilon (Millipore, Billerica, 
MA, USA). Immunoblotting was performed using an anti-
SLC15A2 primary antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and anti-β-actin (Abcam, 
Cambridge, MA, USA). Protein bands were detected using 
WestZol (iNtRon, Gyeonggi, Republic of Korea).
ACKNOWLEDGMENTS
This study was supported by research funding from 
the National Cancer Center (#1130730-1, #1410030, and 
#1510520-1). The bioinformatics work was supported by 
“Bioinformatics platform development for next generation 
bioinformation analysis” by the Ministry of Knowledge 
Economy (MKE, Korea; #10040231). The funders had no 
role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript.
CONFLICTS OF INTEREST
No conflicts of interest were declared.
REFERENCES
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, 
Thun MJ. Cancer statistics. CA Cancer J Clin. 2008; 
58:71–96.
2. EASL-EORTC clinical practice guidelines:  management 
of hepatocellular carcinoma. J Hepatol. 2012; 
56:908–943.
3. Park JW, Sherman M, Colombo M, Roberts L, Schwartz M, 
Degos F, Chen PJ, Chen M, Kudo M, Johnson P, Huang B, 
Orsini LS. Observations of hepatocellular carcinoma (HCC) 
management patterns from the global HCC BRIDGE 
study: first characterization of the full study population. 
J Clin Oncol. 2012; 30. suppl:abstr 4033.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, 
Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, 
Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, 
Galle PR, et al. Sorafenib in advanced hepatocellular 
 carcinoma. N Engl J Med. 2008; 359:378–390.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, 
Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, 
Liu J, Wang J, Tak WY, et al. Efficacy and safety of 
sorafenib in patients in the Asia-Pacific region with 
advanced  hepatocellular carcinoma: a phase III randomised, 
 double-blind, placebo-controlled trial. Lancet Oncol. 2009; 
10:25–34.
6. Bruix J, Sherman M. Management of hepatocellular 
 carcinoma: an update. Hepatology. 2011; 53:1020–1022.
7. Wilhelm SM, Adnane L, Newell P, Villanueva A, 
Llovet JM, Lynch M. Preclinical overview of sorafenib, 
Oncotarget16459www.impactjournals.com/oncotarget
a multikinase inhibitor that targets both Raf and VEGF and 
PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 
2008; 7:3129–3140.
8. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, 
Fong Y, Gores G, Kerlan R, Merle P, O’Neil B, Poon R, 
Schwartz L, Tepper J, Yao F, Haller D, Mooney M, et al. 
Hepatocellular carcinoma: consensus recommendations 
of the National Cancer Institute Clinical Trials Planning 
Meeting. J Clin Oncol. 2010; 28:3994–4005.
9. Kim HY, Park JW. Molecularly targeted therapies for 
 hepatocellular carcinoma: sorafenib as a stepping stone. Dig 
Dis. 2011; 29:303–309.
10. Meyerson M, Gabriel S, Getz G. Advances in  understanding 
cancer genomes through second-generation sequencing. 
Nature reviews Genetics. 2010; 11:685–696.
11. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, 
Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, 
Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira 
Cheetham R, Cox AJ, Ellis DJ, et al. Accurate whole human 
genome sequencing using reversible terminator chemistry. 
Nature. 2008; 456:53–59.
12. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen  L, 
McGuire A, He W, Chen YJ, Makhijani V, Roth GT, 
Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, 
Lupski JR, et al. The complete genome of an individual 
by massively parallel DNA sequencing. Nature. 2008; 
452:872–876.
13. Dimond PF. (2014). Exceptional Responders: The “N of 1” 
Paradigm. (http://www.nxtbook.com/nxtbooks/gen/clinical_ 
omics_issue13/#/6).
14. Sawyers CL. The cancer biomarker problem. Nature. 2008; 
452:548–552.
15. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, 
Bruix J. Plasma biomarkers as predictors of  outcome 
in patients with advanced hepatocellular carcinoma. 
Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2012; 
18:2290–2300.
16. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. 
Early alpha-fetoprotein response predicts treatment 
 efficacy of antiangiogenic systemic therapy in patients 
with advanced hepatocellular carcinoma. Cancer. 2010; 
116:4590–4596.
17. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, 
Chen BB, Wei SY, Cheng AL, Shih TT. Dynamic contrast-
enhanced magnetic resonance imaging biomarkers predict 
survival and response in hepatocellular carcinoma patients 
treated with sorafenib and metronomic tegafur/uracil. 
J Hepatol. 2011; 55:858–865.
18. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, 
Horn L, Schiller J, Villalona-Calero MA, Meyerson M, 
Carbone DP. Oncogenic and sorafenib-sensitive ARAF 
mutations in lung adenocarcinoma. The Journal of clinical 
investigation. 2014; 124:1582–1586.
19. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, 
Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, 
Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, 
Shapiro GI, et al. Activating mTOR mutations in a patient 
with an extraordinary response on a phase I trial of evero-
limus and pazopanib. Cancer discovery. 2014; 4:546–553.
20. Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, 
Woo SM, Nam BH. Phase II study of concurrent transar-
terial chemoembolization and sorafenib in patients with 
unresectable hepatocellular carcinoma. J Hepatol. 2012; 
56:1336–1342.
21. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, 
Poon D, Lee EJ, Chowbay B. Pharmacogenetic profiling 
across the irinotecan pathway in Asian patients with cancer. 
British journal of clinical pharmacology. 2005; 59:415–424.
22. Zhou J, Shephard EA. Mutation, polymorphism and 
 perspectives for the future of human flavin-containing 
monooxygenase 3. Mutation research. 2006; 612:165–171.
23. Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, 
Krueger SK, VanDyke JE, Williams DE, Pajewski NM, 
Wang T, Hines RN. Identification and functional  analysis 
of common human flavin-containing monooxygenase 
3 genetic variants. The Journal of pharmacology and 
 experimental therapeutics. 2007; 320:266–273.
24. Krueger SK, Vandyke JE, Williams DE, Hines RN. The 
role of flavin-containing monooxygenase (FMO) in the 
metabolism of tamoxifen and other tertiary amines. Drug 
metabolism reviews. 2006; 38:139–147.
25. Shen H, Keep RF, Hu Y, Smith DE. PEPT2 (Slc15a2)-
mediated unidirectional transport of cefadroxil from 
cerebrospinal fluid into choroid plexus. The Journal of 
pharmacology and experimental therapeutics. 2005; 
315:1101–1108.
26. Thauvin-Robinet C, Munck A, Huet F, de Becdelievre A, 
Jimenez C, Lalau G, Gautier E, Rollet J, Flori J, Nove-
Josserand R, Soufir JC, Haloun A, Hubert D, Houssin E, 
Bellis G, Rault G, et al. CFTR p.Arg117His associated 
with CBAVD and other CFTR-related disorders. Journal of 
medical genetics. 2013; 50:220–227.
27. Hebestreit H, Sauer-Heilborn A, Fischer R, Kading M, 
Mainz JG. Effects of ivacaftor on severely ill patients with 
cystic fibrosis carrying a G551D mutation. Journal of cystic 
fibrosis : official journal of the European Cystic Fibrosis 
Society. 2013; 12:599–603.
28. Junyent M, Arnett DK, Tsai MY, Kabagambe EK, 
Straka RJ, Province M, An P, Lai CQ, Parnell LD, Shen J, 
Lee YC, Borecki I, Ordovas JM. Genetic variants at the 
PDZ-interacting domain of the scavenger receptor class 
B type I interact with diet to influence the risk of meta-
bolic syndrome in obese men and women. The Journal of 
 nutrition. 2009; 139:842–848.
29. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, 
Shimizu S, Taniwaki M, Inazawa J. Overexpression of 
PDZK1 within the 1q12-q22 amplicon is likely to be 
Oncotarget16460www.impactjournals.com/oncotarget
associated with drug-resistance phenotype in multiple 
myeloma. The American journal of pathology. 2004; 
165:71–81.
30. Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, 
Cavrini G, Nannini M, Fumagalli E, Palassini E, 
Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-
Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 
 transporters genes are associated with prolonged time to 
 progression in unresectable gastrointestinal stromal tumours 
treated with imatinib therapy. Pharmacological research : 
the official journal of the Italian Pharmacological Society. 
2013; 68:1–6.
31. Anderson CM, Thwaites DT. Hijacking solute  carriers 
for proton-coupled drug transport. Physiology. 2010; 
25:364–377.
32. Smith DE, Clemencon B, Hediger MA. Proton-coupled 
oligopeptide transporter family SLC15: physiological, 
pharmacological and pathological implications. Molecular 
aspects of medicine. 2013; 34:323–336.
33. Pinsonneault J, Nielsen CU, Sadee W. Genetic variants 
of the human H+/dipeptide transporter PEPT2: analysis 
of haplotype functions. The Journal of pharmacology and 
experimental therapeutics. 2004; 311:1088–1096.
34. Kim BH, Park J-W, Koh YH, Kim C-M. Clinical charac-
teristics of long-term sorafenib therapy in patients with 
advanced hepatocellular carcinoma. Internaltional Liver 
Cancer Association Meeting. 2012. Abtract:P-201.
35. KLCSG-NCC K. Practice guidelines for management 
of hepatocellular carcinoma. Korean J Hepatol. 2009; 
15:391–423.
36. Kim BH, Park JW, Koh YH, Kin C-M. Clinical character-
istics of long-term responders to sorafenib in patients with 
advanced hepatocellular carcinoma [Abstract]. The 19th 
Annual Meeting of the Korean Association for the Study 
of the Liver. 2013.
37. Kanehisa M. The KEGG database. Novartis Found Symp. 
2002; 247:91–101. discussion 101–103, 119–128, 244–152.
38. Yoo JY, Kim SY, Hwang JA, Hong SH, Shin A, Choi IJ, 
Lee YS. Association Study between Folate Pathway Gene 
Single Nucleotide Polymorphisms and Gastric Cancer in 
Koreans. Genomics & informatics. 2012; 10:184–193.
